John Ford work email
- Valid
- Valid
John Ford personal email
Biotechnology Entrepreneur: Proven track record building and exiting multiple biotechnology companies. Dedicated to bringing new treatments to patients with high unmet medical need.
-
CeoEnterprise TherapeuticsUnited Kingdom
-
Executive ChairmanArmgo Pharma, Inc. Jan 2022 - PresentArdsley, Ny, UsARMGO is developing ARM210 for cardiac, musculoskeletal, and neurological disorders. The company's proprietary drugs, known as Rycals®, are a new class of oral agents that repair calcium leaks through the Ryanodine Receptor. This is based on the research of founding scientist Andrew R. Marks, M.D., Columbia University. -
ChairmanComplement Therapeutics Jul 2021 - PresentMunich, DeComplement Therapeutics is developing a portfolio of treatments for complement-related diseases including age-related macular degeneration, each with a high unmet clinical need. Series A of 72M EUR closed in early 2023. -
CeoEnterprise Therapeutics Oct 2016 - PresentBrighton, East Sussex, GbEnterprise Therapeutics is developing novel muco-regulatory therapies for patients suffering with Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis (CF) and severe asthma. To achieve this the Company is targeting mechanisms that increase the clearance of mucus or reduce levels of mucus production, in order to alleviate the symptoms and complications associated with respiratory disease. In 2020 Roche//Genentech acquired our TMEM16A portfolio for $100M upfront plus undisclosed milestones.
-
Co-Owner & Investor DirectorMetrion Biosciences Jul 2015 - PresentCambridge, GbMetrion Biosciences, a UK-based Contract Research Organization offering high quality ion channel screening services on a fee-for-service or collaboration basis. Collectively, our management team have amassed over 80 years of experience in ion channel drug discovery and our clients can access this high level of expertise as part of our dedicated service. -
Co-Founder & CeoArio Pharma Jul 2013 - Feb 2018Ario Pharma's lead asset, a potentially best-in-class, oral TRPV1 inhibitor was acquired by PILA Pharma and is currently in Phase 2 for Type 2 Diabetes. Ario also developed TRPA1 antagonists for multiple indications.
-
Co-Founder & CsoXention Discovery Aug 2002 - Oct 2016Xention developed novel atrial-selective therapies for the treatment of atrial fibrillation. I was responsible for the IKur/Kv1.5 project that reached Phase 2a and was partnered to Servier for up to €120 million
-
General Manager Uk OperationsAkarna Therapeutics, Ltd Feb 2016 - May 2016Akarna Therapeutics is a biopharmaceutical company that was acquired by Allergan in 2016. The company developed novel small molecule FXR agonists for the treatment of nonalcoholic steatohepatitis (NASH). -
CooDezima Pharma B.V. Jan 2013 - Sep 2015Dezima is a biopharmaceutical company that was acquired by Amgen in 2015 for up to $1.55 billion. Dezima's cholesteryl ester transfer protein (CETP) inhibitor showed significant and clinically relevant decrease of low-density lipoprotein (LDL) levels, and an increase of high-density lipoprotein (HDL) levels in a Phase 2b study that was published in The Lancet. Obicetrapib is currently in Phase 3 CVOT trials - see New Amsterdam Pharma (Nasdaq: NAP)
-
Team LeaderBiofocus Discovery Ltd 1998 - 2002Responsible for cell-based drug discovery camapaigns at Biofocus. Extensive assay development and HTS experience.
John Ford Skills
John Ford Education Details
-
University Of LeedsBiochemistry & Pharmacology -
Robert Smyth Grammar School
Frequently Asked Questions about John Ford
What company does John Ford work for?
John Ford works for Enterprise Therapeutics
What is John Ford's role at the current company?
John Ford's current role is CEO.
What is John Ford's email address?
John Ford's email address is jo****@****ion.com
What schools did John Ford attend?
John Ford attended University Of Leeds, Robert Smyth Grammar School.
What are some of John Ford's interests?
John Ford has interest in Swimming, Racketball, Skiing, Squash.
What skills is John Ford known for?
John Ford has skills like Drug Discovery, Drug Development, Biotechnology, Clinical Development, Clinical Trials, Life Sciences, Assay Development, Pharmaceutical Industry, Pharmacology, High Throughput Screening, Technology Transfer, Ion Channels.
Who are John Ford's colleagues?
John Ford's colleagues are Rob Woodman, Henry Danahay.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial